Biofrontera AG (NASDAQ:BFRA) is set to announce third quarter earning results on Wednesday 11th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BFRA to report 3Q20 loss of $ 0.34 per share.
For the full year, analysts anticipate top line of $ 34.80 million, while looking forward to loss of $ 0.82 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 5.49 million ~ $ 5.73 million
Full Year 2020 topline are forecasted in a range of$ 38.42 million ~ $ 42.94 million
Click Here For More Historical Outlooks Of Biofrontera AG
Previous Quarter Performance
Biofrontera AG revealed income for the second quarter of $ 0.02 per share, from the revenue of $ 10.62 million. The quarterly earnings reduced 96.55 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.16 per share from $ 7.90 million in revenue. The bottom line results beat street analysts by $ 0.18 or 112.50 percent, at the same time, top line results outshined analysts by $ 2.72 million or 34.43 percent.
Stock Performance
Shares of Biofrontera AG traded up $ 0.19 or 2.81 percent on Tuesday, reaching $ 6.94 with volume of 31.50 thousand shares. Biofrontera AG has traded high as $ 7.10 and has cracked $ 6.91 on the downward trend
The closing price of $ 6.94, representing a 28.08 % increase from the 52 week low of $ 5.27 and a 87.73 % decrease over the 52 week high of $ 55.00.
The company has a market capital of $ 166.57 million and is part of the Healthcare sector and Biotechnology industry.
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
